Evidence map›Paper›PMID 30386120›Full record

ArticleAnnals of gastroenterology

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.

Nikolaos Kentepozidis, Panagiota Economopoulou, Michael Liontos, Athanasios Kotsakis, Ioannis Boukovinas, Nikolaos Vardakis, Emmanouil Kontopodis, Efthimios Prinarakis, Teressa Skaltsi, John Souglakos and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Precision medicine in gastric cancer.World journal of gastrointestinal oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nikolaos KentepozidisHellenic Oncology Research Group, Athens, Greece.
Panagiota EconomopoulouHellenic Oncology Research Group, Athens, Greece.
Michael LiontosHellenic Oncology Research Group, Athens, Greece.
Athanasios KotsakisHellenic Oncology Research Group, Athens, Greece.
Ioannis BoukovinasHellenic Oncology Research Group, Athens, Greece.
Nikolaos VardakisHellenic Oncology Research Group, Athens, Greece.
Emmanouil KontopodisHellenic Oncology Research Group, Athens, Greece.
Efthimios PrinarakisHellenic Oncology Research Group, Athens, Greece.
Teressa SkaltsiHellenic Oncology Research Group, Athens, Greece.
John SouglakosHellenic Oncology Research Group, Athens, Greece.
Vassilis GeorgouliasHellenic Oncology Research Group, Athens, Greece.
Hellenic Oncology Research Group · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA phase I/II study to define the maximum tolerated dose (MTD) of biweekly docetaxel/cisplatin/5-fluorouracil (DCF) plus panitumumab (P), its efficacy, and tolerability as first-line treatment in advanced gastroesophageal cancer.

methodsIn phase I part, patients with unresectable locally advanced or metastatic adenocarcinomas of the stomach or the gastroesophageal junction received cisplatin (40 mg/m

resultsThe MTD for docetaxel in the mDCF/P was defined at 40 mg/m

conclusionsmDCF/P combination was feasible, though associated with a poor toxicity profile. However, the study failed to meet its primary endpoint and was terminated prematurely due to futility.

Indexed as

5-fluorouracilcisplatindocetaxelGastroesophageal junction cancerpanitumumab ClinicalTrials.gov Identifier: NCT01716546

Identifiers

PMID30386120
PMCPMC6191861
OpenAlexW2891082096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.